Surgical resection is the first choice of clinical radical treatment for early stage tumors, but 70%-80% of tumor patients belong to the middle and late stage and lose the opportunity of surgery. The main reasons are: recurrence and metastasis after surgery, old age, physical weakness (heart, lung, liver, kidney and other organ functions cannot withstand major traumatic open heart and abdominal surgeries), cancer proliferation, tumors around large blood vessels or adhesions that cannot be surgically stripped. Radiotherapy is usually used for these middle to late stage patients. The toxic side effects and complications of radiotherapy not only make the patients very painful, immunocompromised and weak, but also ineffective in many cases. These patients are in desperate need of a less painful, safe and effective treatment with fewer toxic side effects. The argon helium supercooled knife has invariably become the first choice for these populations. In the past decade, a large amount of relevant clinical data has been published, confirming the safety, efficacy, and minimally invasiveness of Ar-He cryoablation for the treatment of the following inoperable benign and malignant tumors in the middle and late stages of life in the United States. The Ar-He ultracold knife has become the treatment of choice. Ar-He ultracold knife treatment is applicable to a wide range of solid tumors, including. Lung cancer, liver cancer, hepatic hemangioma, breast cancer, breast fibroadenoma, pancreatic cancer, prostate cancer, prostate hyperplasia, kidney cancer, adrenal gland tumor, head and neck tumor, thyroid cancer, skin tumor, melanoma, soft tissue tumor, lymphoma, perineal tumor, uterus cancer, cervical cancer, ovary cancer, **** cancer, hemangioma, osteosarcoma, tonsillar cancer, pharyngeal tumor, nasopharyngeal carcinoma, liposarcoma, Oral cancer, tongue cancer, maxillofacial tumors and so on. In 1998, the U.S. FDA approved, and in 1999, the Chinese State Drug Administration approved the U.S. argon-helium supercooled knife minimally invasive targeted tumor therapy technology for clinical use, which meets the requirements for the treatment of middle- and late-stage tumor patients. Over the past ten years, a large amount of clinical data has been published, confirming the safety, effectiveness and low side effects of Ar-He Ultracold Knife for the treatment of solid tumors, such as liver cancer, lung cancer, prostate cancer, breast cancer, kidney cancer, pancreatic cancer, etc. It is the successor of radiofrequency ablation technology. It is the high-tech tumor treatment after radio frequency ablation technology, microwave, laser, ultrasonic aggregation knife, gamma knife, X-knife, neutron knife. It has significant advantages in the treatment of solid tumors such as lung cancer, liver cancer, breast cancer, kidney tumor and so on. It represents the most advanced level of tumor treatment in the world. The standardized treatment procedure of this new technology has provided the best choice for tumor patients. It can completely destroy the targeted tumor tissues, and most of the 2-10cm tumors can be treated once to achieve the purpose of local ablation, which can quickly and maximally reduce the tumor load, quickly reduce pain and improve the quality of life of the patients, and effectively prolong the life or even cure. Professor Graves of the Department of Surgical Oncology, University of California, USA, for 250 cases of middle and late-stage hepatocellular carcinoma patients who could not withstand conventional surgical resection, the implementation of surgery combined with intraoperative argon-helium supercooled knife treatment, and compared with the early-stage hepatocellular carcinoma patients with conventional surgical clinical treatment group, and the results showed that there was no significant difference in the rate of local recurrence, distant metastasis, and postoperative survival of patients in the two groups. Keio University School of Medicine, Tokyo, Japan, reported 42 cases of argon-helium supercooled knife treatment for middle and advanced hepatocellular carcinoma in the 2002 International Tumor Targeted Therapy Forum in Beijing, and the rate of complete ablation of tumor treatment reached 92.2%, with a total of 85 hepatocellular carcinoma foci treated, and the rate of complete ablation after treatment reached 96.5%.